Takeda Invests $30 Million in Indonesia's Plasma Industry

Takeda Pharmaceutical Company, a leading Japanese bio-pharmaceutical firm, has announced a significant investment of $30 million (approximately Rp 539 billion) to develop a plasma-derived product ecosystem in Indonesia. This initiative aims to establish a network of plasma banks over the next two years, with the first expected to begin operations by 2027, according to the Indonesian Investment Coordinating Board (BKPM).

Rosan P. Roeslani, the head of BKPM, emphasized that this investment reflects growing global investor confidence in Indonesia's prospects, particularly in the high-tech healthcare sector. He noted that the investment is strategic, not only bringing additional capital but also opening opportunities for technology transfer, human resource development, and the creation of high-skilled jobs.

The partnership aligns with Indonesia's economic transformation agenda, which seeks to enhance competitiveness in various strategic sectors, including healthcare. The government hopes that this collaboration will improve public access to essential plasma-derived medicines while also fostering a competitive, innovative, and sustainable bio-pharmaceutical industry.

“This investment is strategic, not only bringing additional capital but also opening opportunities for technology transfer, human resource development, and the creation of high-skilled jobs.”Rosan P. Roeslani, Head of BKPM

Japan has been a key strategic partner for Indonesia in terms of investment. Data from BKPM indicates that Japan was among Indonesia's major investors in the first quarter of 2026, contributing approximately $1 billion. Cumulatively, Japanese investments from 2021 to the first quarter of 2026 reached $18.1 billion, with an average growth rate of 13.2% and creating 299,460 jobs.

Through this investment, Takeda aims to not only bolster its presence in the Indonesian market but also contribute to the development of a robust healthcare infrastructure. The Indonesian government is optimistic that the establishment of plasma banks will enhance the availability of vital medical products and strengthen the country’s position in the global supply chain for healthcare.

Takeda's Existing Footprint

Takeda is not a newcomer to Indonesia's pharmacy shelves. According to ProductList.id, a specialist tracker of Indonesian product registrations, the company already holds 46 products registered with the national food-and-drug authority, BPOM — 34 of them currently active, and eight approved in the past year alone. Tellingly for a plasma play, 13 of those are injectables or infusions — the same route of administration as plasma-derived therapies — alongside some 29 oral medicines and a handful of other forms.

Takeda Indonesia's BPOM-registered products by dosage form. Source: ProductList.id (Indonesia product registration & market intelligence).

While Indonesian outlets like CNBC Indonesia and Detik Finance reported on the broader implications of Takeda's investment, they also highlighted the government's ongoing efforts to enhance the country's financial landscape through the establishment of the Pusat Finansial Internasional Indonesia (PFII), which aims to attract global investors with incentives such as a 50-year tax exemption. This initiative is seen as part of a larger strategy to position Indonesia as a competitive financial hub in the region.

Indonesian coverage stressed the importance of such investments in not just healthcare but also in fostering a conducive environment for foreign capital, whereas the focus in the initial reporting from BKPM was primarily on healthcare benefits and technological advancements. This divergence illustrates the multifaceted nature of foreign investments in Indonesia, where healthcare developments are intertwined with broader economic strategies.